Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE – Get Rating) CFO James E. Fickenscher sold 17,769 shares of the business’s stock in a transaction on Monday, January 23rd. The shares were sold at an average price of $0.60, for a total transaction of $10,661.40. Following the transaction, the chief financial officer now owns 154,736 shares of the company’s stock, valued at $92,841.60. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Zynerba Pharmaceuticals Price Performance
Zynerba Pharmaceuticals stock traded down $0.03 during mid-day trading on Wednesday, hitting $0.60. The company’s stock had a trading volume of 128,532 shares, compared to its average volume of 264,483. The stock has a market cap of $27.45 million, a price-to-earnings ratio of -0.69 and a beta of 1.64. The business has a 50 day moving average price of $0.57 and a 200-day moving average price of $0.84. Zynerba Pharmaceuticals, Inc. has a 12 month low of $0.49 and a 12 month high of $2.94.
Zynerba Pharmaceuticals (NASDAQ:ZYNE – Get Rating) last posted its quarterly earnings results on Monday, November 14th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.01. On average, equities research analysts expect that Zynerba Pharmaceuticals, Inc. will post -0.86 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Institutional Trading of Zynerba Pharmaceuticals
Several hedge funds have recently added to or reduced their stakes in ZYNE. Cetera Advisor Networks LLC bought a new stake in Zynerba Pharmaceuticals in the second quarter worth $28,000. Verition Fund Management LLC bought a new position in shares of Zynerba Pharmaceuticals during the second quarter valued at about $35,000. Jane Street Group LLC bought a new position in shares of Zynerba Pharmaceuticals during the third quarter valued at about $46,000. UBS Group AG raised its stake in shares of Zynerba Pharmaceuticals by 145.2% during the first quarter. UBS Group AG now owns 27,621 shares of the company’s stock valued at $56,000 after acquiring an additional 16,357 shares during the last quarter. Finally, Two Sigma Investments LP bought a new position in shares of Zynerba Pharmaceuticals during the third quarter valued at about $90,000. 23.82% of the stock is owned by institutional investors.
About Zynerba Pharmaceuticals
Zynerba Pharmaceuticals, Inc engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. It focuses on the research and development of rare and near-rare neuropsychiatric conditions. The firm offers the Zygel product, which is formulated as a permeation-enhanced gel for transdermal delivery.
- Get a free copy of the StockNews.com research report on Zynerba Pharmaceuticals (ZYNE)
- Is The Bottom In For Cyber-Security Stocks?
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.